GLENMARK LIFE SCIENCES
Quarterly Results Analysis [Dec2023]
GLENMARK LIFE SCIENCES Quarterly Results
Standalone | Dec2023 Audited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 Audited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹573 Cr | ₹595 Cr | ₹578 Cr | ₹621 Cr | ₹541 Cr | ₹509 Cr | ₹490 Cr | ₹514 Cr |
Expenses | ₹400 Cr | ₹428 Cr | ₹385 Cr | ₹415 Cr | ₹395 Cr | ₹366 Cr | ₹343 Cr | ₹372 Cr |
Operating Income | ₹173 Cr | ₹167 Cr | ₹193 Cr | ₹206 Cr | ₹145 Cr | ₹144 Cr | ₹147 Cr | ₹142 Cr |
Other Income | ₹2 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹7 Cr | ₹10 Cr | ₹9 Cr | ₹5 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹12 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr |
Profit Before Tax | ₹161 Cr | ₹159 Cr | ₹182 Cr | ₹198 Cr | ₹141 Cr | ₹144 Cr | ₹146 Cr | ₹138 Cr |
Profit After Tax | ₹119 Cr | ₹119 Cr | ₹135 Cr | ₹146 Cr | ₹105 Cr | ₹107 Cr | ₹109 Cr | ₹99 Cr |
EPS | ₹9.69 | ₹9.69 | ₹11.05 | ₹11.95 | ₹8.57 | ₹8.72 | ₹8.87 | ₹8.07 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLENMARK LIFE SCIENCES | 4.3% | -13.3% | 82.6% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
GLENMARK LIFE SCIENCES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -3.79 % |
Y-o-Y | 5.93 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹573 Cr | -3.79 | |
Sep2023 | ₹595 Cr | 2.92 | |
Jun2023 | ₹578 Cr | -6.90 | |
Mar2023 | ₹621 Cr | 14.90 | |
Dec2022 | ₹541 Cr | 6.17 | |
Sep2022 | ₹509 Cr | 3.97 | |
Jun2022 | ₹490 Cr | -4.71 | |
Mar2022 | ₹514 Cr | - |
GLENMARK LIFE SCIENCES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 3.27 % |
Y-o-Y | 18.63 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹173 Cr | 3.27 | |
Sep2023 | ₹167 Cr | -13.50 | |
Jun2023 | ₹193 Cr | -6.43 | |
Mar2023 | ₹206 Cr | 41.92 | |
Dec2022 | ₹145 Cr | 1.26 | |
Sep2022 | ₹144 Cr | -2.13 | |
Jun2022 | ₹147 Cr | 3.20 | |
Mar2022 | ₹142 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 7.34 % |
Y-o-Y | 11.97 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 30.12% | 7.34 | |
Sep2023 | 28.06% | -15.96 | |
Jun2023 | 33.39% | 0.51 | |
Mar2023 | 33.22% | 23.49 | |
Dec2022 | 26.9% | -4.61 | |
Sep2022 | 28.2% | -5.87 | |
Jun2022 | 29.96% | 8.32 | |
Mar2022 | 27.66% | - |
GLENMARK LIFE SCIENCES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 0.02 % |
Y-o-Y | 13.12 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹119 Cr | 0.02 | |
Sep2023 | ₹119 Cr | -12.34 | |
Jun2023 | ₹135 Cr | -7.45 | |
Mar2023 | ₹146 Cr | 39.40 | |
Dec2022 | ₹105 Cr | -1.76 | |
Sep2022 | ₹107 Cr | -1.71 | |
Jun2022 | ₹109 Cr | 9.95 | |
Mar2022 | ₹99 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 3.96 % |
Y-o-Y | 6.75 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 20.73 % | 3.96 | |
Sep2023 | 19.94 % | -14.86 | |
Jun2023 | 23.42 % | -0.59 | |
Mar2023 | 23.56 % | 21.32 | |
Dec2022 | 19.42 % | -7.48 | |
Sep2022 | 20.99 % | -5.45 | |
Jun2022 | 22.2 % | 15.38 | |
Mar2022 | 19.24 % | - |
GLENMARK LIFE SCIENCES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 0.00 % |
Y-o-Y | 13.07 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹9.69 | 0.00 | |
Sep2023 | ₹9.69 | -12.31 | |
Jun2023 | ₹11.05 | -7.53 | |
Mar2023 | ₹11.95 | 39.44 | |
Dec2022 | ₹8.57 | -1.72 | |
Sep2022 | ₹8.72 | -1.69 | |
Jun2022 | ₹8.87 | 9.91 | |
Mar2022 | ₹8.07 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD